Dashboard
Manage Tickers

MNKDMANNKIND CORP

Nasdaq mannkindcorp.com


$ 4.58 $ 0.00 (0 %)    

Friday, 17-May-2024 15:59:59 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 451.63 $ -0.22 (-0.05 %)
DIA $ 399.76 $ 0.74 (0.19 %)
SPY $ 529.24 $ 0.76 (0.14 %)
TLT $ 91.40 $ -0.62 (-0.67 %)
GLD $ 223.63 $ 3.63 (1.65 %)
$ 4.59
$ 4.61
$ 0.00 x 0
$ 0.00 x 0
$ 4.51 - $ 4.61
$ 3.17 - $ 5.75
2,115,885
na
1.49B
$ 1.13
$ 175.62
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-08-2024 03-31-2024 10-Q
2 02-27-2024 12-31-2023 10-K
3 11-07-2023 09-30-2023 10-Q
4 08-07-2023 06-30-2023 10-Q
5 05-09-2023 03-31-2023 10-Q
6 02-23-2023 12-31-2022 10-K
7 11-08-2022 09-30-2022 10-Q
8 08-09-2022 06-30-2022 10-Q
9 05-05-2022 03-31-2022 10-Q
10 02-24-2022 12-31-2021 10-K
11 11-09-2021 09-30-2021 10-Q
12 08-11-2021 06-30-2021 10-Q
13 05-12-2021 03-31-2021 10-Q
14 02-25-2021 12-31-2020 10-K
15 11-04-2020 09-30-2020 10-Q
16 08-05-2020 06-30-2020 10-Q
17 05-06-2020 03-31-2020 10-Q
18 02-25-2020 12-31-2019 10-K
19 11-08-2019 09-30-2019 10-Q
20 08-07-2019 06-30-2019 10-Q
21 05-07-2019 03-31-2019 10-Q
22 02-26-2019 12-31-2018 10-K
23 11-01-2018 09-30-2018 10-Q
24 08-02-2018 06-30-2018 10-Q
25 05-09-2018 03-31-2018 10-Q
26 02-27-2018 12-31-2017 10-K
27 11-07-2017 09-30-2017 10-Q
28 08-07-2017 06-30-2017 10-Q
29 05-10-2017 03-31-2017 10-Q
30 03-16-2017 12-31-2016 10-K
31 11-09-2016 09-30-2016 10-Q
32 08-09-2016 06-30-2016 10-Q
33 05-09-2016 03-31-2016 10-Q
34 03-15-2016 12-31-2015 10-K
35 11-09-2015 09-30-2015 10-Q
36 08-10-2015 06-30-2015 10-Q
37 05-11-2015 03-31-2015 10-Q
38 03-02-2015 12-31-2014 10-K
39 11-10-2014 09-30-2014 10-Q
40 08-11-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

cantor-fitzgerald-reiterates-overweight-on-mannkind-maintains-65-price-target
Cantor Fitzgerald Reiterates Overweight on...
05/09/2024 14:56:24

Cantor Fitzgerald analyst Olivia Brayer reiterates MannKind (NASDAQ:MNKD) with a Overweight and maintains $6.5 price target.

mannkind-q1-2024-adj-eps-005-beats-003-estimate-sales-66263m-beat-60490m-estimate
MannKind Q1 2024 Adj EPS $0.05 Beats $0.03...
05/08/2024 20:42:59

MannKind (NASDAQ:MNKD) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $0.03 by 66....

mannkind-announced-the-fda-fast-track-designation-for-clofazimine-inhalation-suspension-mnkd-101-for-nontuberculous-mycobacterial-lung-disease
MannKind Announced The FDA Fast Track Desi...
05/06/2024 10:10:08

mannkind-will-proceed-with-phase-1-nintedanib-dpi-mnkd-201-study-for-pulmonary-fibrotic-diseases
MannKind Will Proceed With Phase 1 Ninteda...
04/30/2024 10:07:46

mannkind-announces-ind-clearance-from-us-fda-to-start-phase-3-study-of-clofazimine-inhalation-suspension-for-nontuberculous-mycobacterial-ntm-lung-disease
MannKind Announces IND Clearance From US F...
04/29/2024 10:07:05

MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of innovative inhaled therapeuti...

mannkind-announced-that-it-has-repaid-in-full-all-outstanding-indebtedness-under-both-its-credit-and-security-agreement-with-midcap-financial-trust-and-its-convertible-promissory-note-issued-to-mann-group-llc
MannKind Announced That It Has Repaid In F...
04/03/2024 10:06:44

Credit and security agreement with MidCap Financial Trust repaid in full for approximately $31.6 million Convertible note is...

mannkind-appoints-christopher-prentiss-as-cfo-effective-april-22-2024-succeeds-steven-binder
MannKind Appoints Christopher Prentiss As ...
03/26/2024 20:07:38

cantor-fitzgerald-reiterates-overweight-on-mannkind-maintains-65-price-target
Cantor Fitzgerald Reiterates Overweight on...
03/15/2024 14:51:51

Cantor Fitzgerald analyst Olivia Brayer reiterates MannKind (NASDAQ:MNKD) with a Overweight and maintains $6.5 price target.

why-mesoblast-shares-are-trading-higher-by-13-here-are-other-stocks-moving-in-mondays-mid-day-session
Why Mesoblast Shares Are Trading Higher By...
03/11/2024 17:41:28

Shares of Mesoblast Limited (NASDAQ: MESO) rose sharply during Monday’s session after the company announced FDA support of an ...

eqt-genie-energy-and-other-big-stocks-moving-lower-on-monday
EQT, Genie Energy And Other Big Stocks Mov...
03/11/2024 14:37:32

U.S. stocks were lower, with the Dow Jones index falling more than 150 points on Monday.

whats-going-on-with-mannkind-stock
What's Going On With MannKind Stock?
03/11/2024 14:28:31

MannKind Corporation shares are trending on social media Monday. CNBC's Jim Cramer mentioned the stock on the "Mad Mone...

mannkind-announced-initial-meal-challenge-data-from-inhale-3-phase-4-us-trial-comparing-afrezza-head-to-head-with-multiple-daily-injections-and-insulin-pumps
MannKind Announced Initial Meal Challenge ...
03/11/2024 10:13:58

Post-meal hyperglycemia was significantly reduced by 20% with inhaled insulin compared with rapid-acting insulin delivered th...

cramer-says-sprout-social-is-in-a-hot-spot-but-this-energy-stock-is-too-down-and-out
Cramer Says Sprout Social Is In A 'Hot Spo...
03/08/2024 14:13:15

On CNBC’s "Mad Money Lightning Round," Jim Cramer said he needs to do more work on Sprout Social, Inc. (NASDAQ: SPT) ...

mannkind-announced-that-new-clinical-data-from-inhale-3-phase-4-study-of-inhaled-insulin-plus-basal-vs-standard-of-care-at-the-international-conference-on-advanced-technologies-and-treatments-for-diabetes
MannKind Announced That New Clinical Data ...
03/05/2024 11:08:06

cantor-fitzgerald-reiterates-overweight-on-mannkind-maintains-65-price-target
Cantor Fitzgerald Reiterates Overweight on...
02/28/2024 16:22:52

Cantor Fitzgerald analyst Olivia Brayer reiterates MannKind (NASDAQ:MNKD) with a Overweight and maintains $6.5 price target.

mannkind-q4-2023-adj-eps-002-beats-undefined-estimate-sales-5847m-beat-5358m-estimate
MannKind Q4 2023 Adj EPS $0.02 Beats undef...
02/27/2024 21:05:16

MannKind (NASDAQ:MNKD) reported quarterly earnings of $0.02 per share which beat the analyst consensus estimate of undefined by...

earnings-scheduled-for-february-27-2024
Earnings Scheduled For February 27, 2024
02/27/2024 10:01:31

Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on rev...

mannkind-earnings-preview
MannKind Earnings Preview
02/26/2024 20:01:36

mannkind-has-enrolled-305-patients-with-type-1type-2-diabetes-in-inhale-1-study-for-inhaled-insulin-in-pediatric-population-primary-endpoint-analysis-is-expected-in-4q-2024-and-data-dissemination-and-fda-submission-expected-in-2025
MannKind Has Enrolled 305 Patients With Ty...
02/15/2024 11:21:22

hc-wainwright--co-reiterates-buy-on-mannkind-maintains-75-price-target
HC Wainwright & Co. Reiterates Buy on Mann...
01/04/2024 11:29:34

HC Wainwright & Co. analyst Oren Livnat reiterates MannKind (NASDAQ:MNKD) with a Buy and maintains $7.5 price target.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION